Abstract
Psoriasis is a chronic inflammatory systemic disease involving 2-3 % of caucasian population. Severe psoriasis considerably restricts the quality of life, it is associated with other systemic inflammatory diseases and may decrease the life expectancy.
Patients need the long-time effective, nevertheless safe, treatment. Recently, our therapeutic possibilities have expanded due to introduction of a new biological therapy affecting main cytokines involved in the pathogenesis of psoriasis.
To achieve individual optimal treatment the choice of biologic therapy in particular patient should be based on the clinical picture and type of psoriasis, on the previous therapy and disease course as well as on the presence of the accompanying diseases. Presented Czech guidelines follow the available up-to-date international guidelines for psoriasis treatment created by the renowned dermatology committees, namely the latest Anglo-american and German guidelines for biological treatment of psoriasis and the guidelines of rheuumatologic societies.
The guidelines had been subjected to expert consultation procedures and were approved by the committee of the Czech Society of Dermatology and Venereology of the Czech Medical Association of J. E.
Purkyne.